Ann: Mesoblast Raises US$110M Led By US Strategic Investor Group, page-77

$2.38, thank you. Too many retail investors listening to AFR/PWC on things they should have already known. Expect far less cash burn with trials having been completed and now onto some nice partnerships and well funded trials.

This is a specialist orthopedic fund who clearly recognises the science, mechanisms of treatment and huge potential of MSB. I was only explaining their CLBP trials/results to a mate with DDD and a good understanding of the pathology and he was mesmerized as no doubt many informed investors like these guys are by the prospects.